Interventional technology provider AngioDynamics of Queensbury, NY, announced that the U.S. Food and Drug Administration has given clearance for its soon-to-be subsidiary, Oncobionic, to market Irreversible Electroporation (IRE), a technology that allows for surgical ablation of soft tissue, including cardiac and smooth muscle.
IRE uses needles and image guidance similar to existing thermal ablation tools, but rather than burning or freezing the tissue, IRE disturbs the cell membrane and destroys the targeted cells. IRE's advantages include faster delivery of ablation energy, clearly defined treatment margins, and complete destruction of tissue next to large vessels, according to AngioDynamics.
AngioDynamics made a bid to acquire Oncobionic in October with an initial cash deposit of $5 million, and additional $20 million in cash payments to be made over two years. The acquisition will be final once IRE has been successfully tested for human use. AngioDynamics expects this testing to begin mid-2007.
By AuntMinnie.com staff writers
November 28, 2006
Related Reading
AngioDynamics to acquire Oncobionic, October 18, 2006
AngioDynamics posts profitable Q4, '06, August 11, 2006
AngioDynamics launches new PICC kit, May 9, 2006
AngioDynamics files patent suit, January 4, 2006
AngioDynamics net sales, income climb in Q2, December 20, 2005
Copyright © 2006 AuntMinnie.com
